GENPREX (GNPX) Competitors $0.26 -0.01 (-2.59%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$0.26 +0.00 (+0.76%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GNPX vs. CARA, TENX, LSTA, CYTH, FBLG, KLTO, NNVC, BCAB, SNYR, and CMMBShould you be buying GENPREX stock or one of its competitors? The main competitors of GENPREX include Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Lisata Therapeutics (LSTA), Cyclo Therapeutics (CYTH), FibroBiologics (FBLG), Klotho Neurosciences (KLTO), NanoViricides (NNVC), BioAtla (BCAB), Synergy CHC (SNYR), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry. GENPREX vs. Its Competitors Cara Therapeutics Tenax Therapeutics Lisata Therapeutics Cyclo Therapeutics FibroBiologics Klotho Neurosciences NanoViricides BioAtla Synergy CHC Chemomab Therapeutics Cara Therapeutics (NASDAQ:CARA) and GENPREX (NASDAQ:GNPX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership. Is CARA or GNPX more profitable? GENPREX has a net margin of 0.00% compared to Cara Therapeutics' net margin of -1,099.76%. Cara Therapeutics' return on equity of -367.97% beat GENPREX's return on equity.Company Net Margins Return on Equity Return on Assets Cara Therapeutics-1,099.76% -367.97% -107.43% GENPREX N/A -664.65%-370.18% Do institutionals & insiders believe in CARA or GNPX? 44.7% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 14.1% of GENPREX shares are owned by institutional investors. 3.1% of Cara Therapeutics shares are owned by company insiders. Comparatively, 8.5% of GENPREX shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has preferable earnings & valuation, CARA or GNPX? GENPREX has lower revenue, but higher earnings than Cara Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCara Therapeutics$7.14M0.00-$118.51M-$21.01N/AGENPREXN/AN/A-$21.11MN/AN/A Does the media favor CARA or GNPX? In the previous week, Cara Therapeutics' average media sentiment score of 0.00 equaled GENPREX'saverage media sentiment score. Company Overall Sentiment Cara Therapeutics Neutral GENPREX Neutral Which has more risk and volatility, CARA or GNPX? Cara Therapeutics has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, GENPREX has a beta of -0.5, indicating that its share price is 150% less volatile than the S&P 500. SummaryCara Therapeutics beats GENPREX on 5 of the 8 factors compared between the two stocks. Get GENPREX News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNPX vs. The Competition Export to ExcelMetricGENPREXMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.24M$2.92B$5.56B$9.05BDividend YieldN/A2.44%5.24%3.99%P/E RatioN/A21.5627.6520.23Price / SalesN/A283.26419.56119.26Price / CashN/A41.7026.2128.59Price / Book1.757.538.035.65Net Income-$21.11M-$55.14M$3.18B$249.15M7 Day Performance19.55%4.61%2.93%3.28%1 Month Performance-8.55%0.90%1.72%3.95%1 Year Performance-86.16%5.40%34.39%20.98% GENPREX Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNPXGENPREX1.0404 of 5 stars$0.26-2.6%N/A-86.2%$7.24MN/A0.0020Gap DownCARACara Therapeutics0.3356 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580News CoverageGap DownHigh Trading VolumeTENXTenax Therapeutics1.265 of 5 stars$5.76-1.5%$17.50+203.8%+89.8%$24.27MN/A-2.329LSTALisata Therapeutics2.4857 of 5 stars$2.90+3.6%$15.00+417.2%-24.8%$24.12M$1M-1.2630Gap DownCYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870.73K-0.809FBLGFibroBiologics2.5362 of 5 stars$0.62+0.7%$13.00+1,989.4%-87.0%$23.65MN/A0.0010Gap UpKLTOKlotho NeurosciencesN/A$1.13+56.9%N/AN/A$23.40MN/A0.00N/AAnalyst UpgradeHigh Trading VolumeNNVCNanoViricides1.0876 of 5 stars$1.40flatN/A-20.0%$22.50MN/A-1.9420BCABBioAtla2.7283 of 5 stars$0.40+3.1%$5.00+1,162.6%-71.2%$22.43M$11M-0.3260News CoverageGap DownSNYRSynergy CHC3.7613 of 5 stars$2.85+17.3%$10.00+250.9%N/A$22.34M$34.83M0.0040Gap UpHigh Trading VolumeCMMBChemomab Therapeutics2.9033 of 5 stars$1.16-0.9%$8.50+632.8%+19.8%$22.06MN/A-1.5320 Related Companies and Tools Related Companies CARA Competitors TENX Competitors LSTA Competitors CYTH Competitors FBLG Competitors KLTO Competitors NNVC Competitors BCAB Competitors SNYR Competitors CMMB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNPX) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENPREX Please log in to your account or sign up in order to add this asset to your watchlist. Share GENPREX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNPX Stock Alerts